Slide 1: Silicon Nitride: The Material Difference
Silicon Nitride The Material Difference® Transforming Medicine with the Ideal BiomaterialTM 1
Slide 2: Forward-Looking Statement Disclaimer
FORWARD-LOOKING STATEMENT DISCLAIMER The Material Difference This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding our strategy; market opportunities; co
Slide 3: The Problem with Current Biomaterials
THE PROBLEM WITH CURRENT BIOMATERIALS The Material Difference ▪ Metal implants containing Ni & Co can be allergenic ▪ PEEK devices are inert with no osteogenic properties ▪ Neither Polymers nor Metal are antimicrobial Silicon Nitride devices are Osteogenic and Antimicrobial *Subject to regulatory re
Slide 4: SiNERGY Si3N4 – The Ideal Biomaterial
SiNERGY® Si3N4 – THE IDEAL BIOMATERIAL The Material Difference SiNERGY® is a bioactive ceramic with unique surface chemistry ideal for use in medical device applications. FEATURES: ▪ Kills 99.9% of Gram-positive and Gram-negative bacteria3 ▪ Stimulates accelerated proliferation of Osteoblast cells1
Slide 5: Material Comparison
MATERIAL COMPARISON Biological and Infection Behavior Property Silicon Nitride Titanium PEEK Findings published in peer-reviewed Osteogenic Response ✓1 ✓ ✕ publications Osseointegration ✓2 ✓ ✕ demonstrate that: Bacterial Adhesion ✓ Reduced3,4 ✕ ✕ “Silicon nitride is both Biofilm Formation ✓ Reduced3
Slide 6: Core Strengths
CORE STRENGTHS Strong IP and Regulatory Portfolio ▪ 21 U.S. issued patents ▪ Maintain 4+ comprehensive FDA Master Files ▪ FDA 510k 12+ (Spine and Foot & Ankle) Research and Scientific Achievements ▪ Research independently corroborated ▪ 15 SBIR/STTR grants awarded, $4,338,665 received ▪ 180+ peer-re
Slide 7: Facility and Physical Asset Summary
FACILITY AND PHYSICAL ASSET SUMMARY Physical Plant in Salt Lake City, Utah ▪ 21,450 sq. ft of manufacturing floor space; 11,500 sq. ft. of office space ▪ Capable of both subtractive and additive (3D) Manufacturing ▪ Vertically integrated for silicon nitride manufacturing ▪ Inspection equipment for v
Slide 8: Silicon Nitride – Formulations
SILICON NITRIDE – FORMULATIONS The Material Difference Silicon Nitride Silicon Nitride Silicon Nitride Silicon Nitride MONOLITHIC CERAMICS COMPOSITES COATINGS POWDER ▪ Subtractive Manufactured ▪ SiN / PEEK ▪ SiN Coating ▪ Fabrics ▪ Additively Manufactured ▪ SiN / PEKK ▪ SiN / PAEK Coating ▪ Fibers (
Slide 9: Orthopedic, Spine and Other Market Sizes
ORTHOPEDIC, SPINE AND OTHER MARKET SIZES Global Orthopedic Sales Totaled $61.9 Billion in 2024 $22.6B $10.8B $9.1B $7.1B $12.3B $10.6B $8.8B Enabling Technology & Other $6.6B $5.7B $3.2B PROPRIETARY AND CONFIDENTIAL 1 ORTHOWORLD Inc 2024 Industry Annual Report ©2026 SINTX TECHNOLOGIES – CONFIDENTIAL
Slide 10: Cost of Implant Associated Infections
Cost of Implant Associated Infections The Unmet Clinical Need $3 to $5 billion: Total cost of MSK implant associated-infections to the US healthcare system. Breakdown by Fixation Type: ▪ Fracture Fixation Hardware: $1 – 1.5 billion annually ▪ Large Joint Periprosthetic Infections: $1.8 – 2.2 billion
Slide 11: Near-Term (0-18 Months) Commercial Strategy
NEAR-TERM (0-18 MONTHS) COMMERCIAL STRATEGY Internal Sales Coverage Model ▪ SiNAPTIC® Foot & Ankle Wedges (SiNERGY) FDA 510(k) Devices ▪ Lower Extremity Personalized Implants (SiNERGY Biocomposite) FDA 520(b) Customs > 510(k) Patient Specific ▪ Lower Extremity Personalized Cutting Guides FDA 520(b)
Slide 12: SiNAPTIC Foot & Ankle Osteotomy Wedge System
SiNAPTIC® FOOT & ANKLE OSTEOTOMY WEDGE SYSTEM Entering Full Launch: Cotton, Evans and Subtalar ©2026 SINTX TECHNOLOGIES – CONFIDENTIAL – DO NOT DISTRIBUTE
Slide 13: Surgeon User Commercial Strategy
SURGEON USER COMMERCIAL STRATEGY SiNAPTIC® FOOT & ANKLE OSTEOTOMY WEDGE SYSTEM | SURGEON USER GEOGRAPHY & HEAT MAP 37 West Technology-forward markets + Mountain / Upper Plains expansion 9 Central Core volume + distributor-led execution 12 Northeast Academic density + KOL influence 13 Southeast High-
Slide 14: US Patient Specific 3D Printed Implants
US Patient Specific 3D Printed Implants Market Growth 2026-2036 ▪ 46% are Orthopedic applications ▪ 14% of those to treat Oncology ▪ 8.3% Global CAGR *Future Market Insights Market Analysis; Patient Specific Surgical Implants Market *Patient Specific Surgical Implants Market to reach $11.5B by 2036
Slide 15: US Patient Specific Implants
US Patient Specific Implants Orthopedic Trauma & Oncology Implant Market Growth 2026-2036 *Future Market Insights Market Analysis; Patient Specific Surgical Implants Market *Orthopedic 3D Printing Devices Market Aug ’25, Report ID: 02850678 *Future Market Insights Market Analysis; Patient Specific S
Slide 16: US Patient Specific Implants
US Patient Specific Implants Cranial & CMF Implant Market Growth 2026-2036 ▪ US is ~40% of global market ▪ Customizable Plates ~68% ▪ Custom Bone Replacement ~32% *Future Market Insights Market Analysis; Patient Specific Surgical Implants Market *Patient Specific Surgical Implants Market to reach $1
Slide 17: Patient-Specific Device Workflow
PATIENT-SPECIFIC DEVICE WORKFLOW Rapid Response to Trauma with The Ideal Biomaterial *Illustrative design workflow only. Patient-specific silicon nitride implants are not currently cleared for all clinical indications. Regulatory requirements vary by device. ©2026 SINTX TECHNOLOGIES – CONFIDENTIAL –
Slide 18: SINTX Signs Agreement with Evonik for SiN-PEEK Compound
SINTX Signs Agreement with to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants Milestone Enables Production Of SiN / PEEK Custom Devices Why the SINTX–EVONIK Agreement Matters ▪ Working with a Global Giant EVONIK is a $15B+ biomaterials powerhouse, now
Slide 19: The Competition – Market Movers
THE COMPETITION – MARKET MOVERS Provide patient-centric Commercial-stage firm solutions that push the delivering AI-enabled, patient- Developer of customize surgical boundaries of biomaterials to specific spine surgery Specializes in patient-specific solutions designed for patients transform lives a
Slide 20: Silicon Nitride Medical Textiles
SILICON NITRIDE MEDICAL TEXTILES Antimicrobial Medical Textiles Market Opportunity Lead Products ▪ Wound Care: $15B ▪ Wound dressings ▪ Surgical Masks: $7B+ ▪ Surgical sutures ▪ Sutures: $5B ▪ Surgical masks ▪ Drapes & Gowns: $5B+ ▪ Implants & Catheters: $50B+ Next Phase ▪ Negative Pressure Wound Th
Slide 21: Si3N4 Suture Pilot Animal Study
Si3N4 SUTURE PILOT ANIMAL STUDY Antibacterial Wound Study Current Status In Progress Desired Outcomes • SOW executed and project • Final selection of animal model • Generate in vivo evidence of initiated (Nov 2025) and study design parameters antibacterial performance vs. • Study framework defined t
Slide 22: Aerospace Business
Aerospace Business Ceramic Insulators ▪ SINTX manufacturers complex Silicon Nitride Insulators for several multi-national Tier 1 aerospace suppliers ▪ Q2 contract negotiations have yielded price increases raising gross margins over 65% ▪ Received over $3.2m in purchase orders among 3 customers for 2
Slide 23: Executive Leadership Team
EXECUTIVE LEADERSHIP TEAM with Proven Success in Medical Device ERIC K. OLSON GREGG HONIGBLUM RYAN ELMORE CHRIS LYONS KEVIN ONTIVEROS KEVIN TRASK Director Chief Financial Officer CEO, Chairman Chief Investment Officer President Chief Legal Officer • 35 Years – Sales & • 35 year Investment • 15+ Year
Slide 24: Selected Financial Data/Analyst Coverage
Selected Financial Data/Analyst Coverage Q2 ’25 Q2 ’26 Change % Q3 ’26** Q4 ‘26** Product Revenue $100,000 $447,000 347% $0.9 – 1.1m $1.0 – 1.3m Net Loss $(2,318,000) $(2,706,000) 17% ▪ *As filed on Form 10-Q ▪ **Revenue guidance provided for the second half of 2026 Common shares outstanding as of A
Slide 25: Investment Consideration
INVESTMENT CONSIDERATION The Material Difference ▪ Industry-changing technology backed by patents, surgeon validation, and initial outcomes ▪ Full commercialization will commence in Q4 2026 for foot and ankle devices ▪ Transformative partnership with EVONIK (EVKIF) ▪ In discussions with numerous str
Slide 26: Contacts
SINT NasdaqListed Contacts Eric K. Olson Chairman and Chief Executive Officer eolson@sintx.com Gregg Honigblum Chief Investment Officer ghonigblum@sintx.com Investor Relations IR@sintx.com ©2026 SINTX TECHNOLOGIES – CONFIDENTIAL – DO NOT DISTRIBUTE
Slide 27: Appendix
APPENDIX © 2©02205 2 S 6I N S ITNX T T X E TCEHCNHONLOOLGOI G E ISE –S F– OCRO INNFVI E D SE TNOT R I A PL R–E S D EON N TAO TT I O DNI SP TRU IRBPUOTSEE S
Slide 28: Antibacterial Mechanism of SiNERGY Si3N4
Antibacterial Mechanism of SiNERGY Si3N4 The Material Difference SiNERGY Silicon Nitride devices elute Silicon and Nitrogen ions from their surface upon blood contact Nitrogen ions bond with Hydrogen to form Ammonium, Ammonia, and Reactive Nitrogen Species. Ammonia (NH3) penetrates Gram-positive bac
Slide 29: Osteoblast Proliferation due to SiNERGY Si3N4
Osteoblast Proliferation due to SiNERGY Si3N4 The Material Difference Mesenchymal stem cells are released at the surgical site in response to local tissue injury to support repair and healing of bone tissue. MSCs incorporate the free Ammonium (NH4) ions through the glutamine synthetase pathway, comb
Slide 30: 3.5-Log Reduction (99.9% Kill) of S. epidermidis
> 3.5-Log Reduction (99.9% Kill) of S. epidermidis The Material Difference ▪ Experiment began with 1x105 CFUs of S. Epi ▪ SiNERGY* achieved greater than 3.5-Log reduction in 48hrs ▪ 3-Log Bacterial Reduction = 99.9% kill ▪ SiNERGY achieved >10x reduction vs Ti ▪ 1000x reduction vs PEEK 3. Bock, R.M.
Slide 31: Surface Topography of SiNERGY Si3N4 vs Titanium
Surface Topography of SiNERGY Si3N4 vs Titanium The Material Difference SiNERGY Machined Silicon Nitride Ti6Al4V 4. Pezzotti et. al. “Human osteoblasts grow transitional Si/N apatite in quickly osteointegrated Si3N4 cervical insert." Acta Biomateriala, 64 (2017) 411-420 5. Webster et. al., “Anti-inf
Slide 32: Global Patient Specific 3D Printed Implants
Global Patient Specific 3D Printed Implants Market Growth 2026-2036 *Future Market Insights Market Analysis; Patient Specific Surgical Implants Market *Patient Specific Surgical Implants Market to reach $11.5B by 2036 *Future Market Insights Market Analysis; Patient Specific Surgical Implants Market